BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30157114)

  • 21. Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT).
    Meredith TA; McCannel CA; Barr C; Doft BH; Peskin E; Maguire MG; Martin DF; Prenner JL;
    Ophthalmology; 2015 Apr; 122(4):817-21. PubMed ID: 25600198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endophthalmitis after intravitreal injection: the importance of viridans streptococci.
    Chen E; Lin MY; Cox J; Brown DM
    Retina; 2011 Sep; 31(8):1525-33. PubMed ID: 21878800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center.
    Gonzalez-Gonzalez LA; Knickelbein JE; Doft BH; Balasubramani GK; Wisniewski S
    Int Ophthalmol; 2023 Mar; 43(3):867-876. PubMed ID: 36103102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.
    Gregori NZ; Flynn HW; Schwartz SG; Rosenfeld PJ; Vaziri K; Moshfeghi AA; Fortun JA; Kovach JL; Dubovy SR; Albini TA; Davis JL; Berrocal AM; Smiddy WE
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):643-8. PubMed ID: 26114845
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of endophthalmitis after intravitreal injection of antivascular endothelial growth factor medications using topical lidocaine gel anesthesia.
    Inman ZD; Anderson NG
    Retina; 2011 Apr; 31(4):669-72. PubMed ID: 21178659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome.
    Dossarps D; Bron AM; Koehrer P; Aho-Glélé LS; Creuzot-Garcher C;
    Am J Ophthalmol; 2015 Jul; 160(1):17-25.e1. PubMed ID: 25892127
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in Kuwait.
    Wani VB; Al-Kandari J; Sabti K; Aljassar F; Qali H; Kumar N; Uboweja A; Al-Sabah K; Diab FA; Al-Rashidi S
    Middle East Afr J Ophthalmol; 2016; 23(1):64-70. PubMed ID: 26957841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular Degeneration Patients Treated with Intravitreal Anti-Vascular Endothelial Growth Factor Injections.
    Sagiv O; Zloto O; Moroz I; Moisseiev J
    Ophthalmologica; 2017; 238(4):217-225. PubMed ID: 28926846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. INFLAMMATORY CHOROIDAL NEOVASCULAR MEMBRANE: Long-Term Visual and Anatomical Outcomes After Intravitreal Anti-vascular Endothelial Growth Factor Therapy.
    Dʼsouza P; Ranjan R; Babu U; Kanakath AV; Saravanan VR
    Retina; 2018 Jul; 38(7):1307-1315. PubMed ID: 28520642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.
    Kanchanaranya N; Rojdamrongratana D; Piyasoonthorn P
    J Med Assoc Thai; 2015 May; 98(5):489-94. PubMed ID: 26058278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Study of Microbiological Profile and Management Outcomes of Acute Endophthalmitis after Microincision Vitrectomy Surgery versus Intravitreal Injections.
    Kannan NB; Sen S; Mishra C; Lalitha P; Rameshkumar G; Rajan RP; Arumugam KK; Ramasamy K
    Ocul Immunol Inflamm; 2021 Jul; 29(5):838-844. PubMed ID: 31900009
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluation of the incidence of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor.
    Inoue M; Kobayakawa S; Sotozono C; Komori H; Tanaka K; Suda Y; Matsushima H; Kinoshita S; Senoo T; Tochikubo T; Kadonosono K
    Ophthalmologica; 2011; 226(3):145-50. PubMed ID: 21811052
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LONG-TERM USE OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Begaj T; Jeong D; Park JG; Runner MM; Capone A; Dass AB; Drenser KA; Faia LJ; Farley ND; Garretson BR; Hassan TS; Mahmoud TH; Margherio A; Raphaelian PV; Randhawa S; Ruby AJ; Sneed S; Rao P; Wolfe JD; Williams GA
    Retina; 2024 Feb; 44(2):222-229. PubMed ID: 37903288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DELAYED-ONSET STREPTOCOCCUS INTERMEDIUS ENDOPHTHALMITIS FOLLOWING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INTRAVITREAL INJECTION.
    Mercer GD; Politis M; Campagnoli TR; Galic IJ; Chen JC
    Retin Cases Brief Rep; 2022 Nov; 16(6):688-690. PubMed ID: 33165298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical characteristics of endophthalmitis after an injection of intravitreal antivascular endothelial growth factor.
    Mezad-Koursh D; Goldstein M; Heilwail G; Zayit-Soudry S; Loewenstein A; Barak A
    Retina; 2010; 30(7):1051-7. PubMed ID: 20616683
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visual Outcome of Anti-vascular Endothelial Growth Factor Injections at the University College Hospital, Ibadan.
    Oluleye TS; Babalola YO; Majekodunmi O; Ijaduola M; Adewole AT
    Ann Afr Med; 2021; 20(4):276-281. PubMed ID: 34893565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration.
    Kvannli L; Krohn J
    Acta Ophthalmol; 2017 Nov; 95(7):678-682. PubMed ID: 28139082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Endophthalmitis following intravitreal injections.
    Irigoyen C; Ziahosseini K; Morphis G; Stappler T; Heimann H
    Graefes Arch Clin Exp Ophthalmol; 2012 Apr; 250(4):499-505. PubMed ID: 22048244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suspected bacterial endophthalmitis following intravitreal anti-VEGF injection: case series and literature review.
    Hoevenaars NE; Gans D; Missotten T; van Rooij J; Lesaffre E; van Meurs JC
    Ophthalmologica; 2012; 228(3):143-7. PubMed ID: 22796790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.
    Freiberg FJ; Brynskov T; Munk MR; Sørensen TL; Wolf S; Wirth MA; Becker M; Michels S
    Retina; 2017 Dec; 37(12):2341-2346. PubMed ID: 28099318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.